BOULDER, Colo., Nov. 1, 2012 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will hold a conference call on Monday, November 5, 2012 at 4:30 p.m. Eastern Time to discuss submitted 2012 American Society of Hematology Annual Meeting abstracts on ARRY-520, a KSP inhibitor for multiple myeloma and ARRY-614, a dual p38/Tie2 inhibitor for myelodysplastic syndromes. Ron Squarer, Chief Executive Officer and Kevin Koch, Ph.D., President and Chief Scientific Officer, will lead the call.
Conference Call Information
Monday, November 5, 2012
4:30 p.m. Eastern Time
Webcast & Conference Call Slides: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome
A replay of the call will be available as a webcast on www.arraybiopharma.com
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small‑molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly‑owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. For more information on Array, please go to www.arraybiopharma.com.
SOURCE Array BioPharma Inc.